AEON Biopharma Phase 2 trial of ABP-450 for chronic migraine fails primary endpoint

AEON Biopharma, Inc.

Primary endpoint: mean reduction in monthly migraine days (MMD) at weeks 13-24 was 8.5 (150U), 7.7 (195U), 8.4 (placebo); p=0.9132 and 0.3611.
Trial did not achieve statistical significance for primary or any secondary endpoints; placebo response was unexpectedly higher than historical studies.
Company immediately commencing cash preservation measures and reviewing all strategic options for ABP-450 development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.